Abstract
Prior research shows that topical application of free, non-fatty acid conjugated vitamin E (dl-α-tocopherol) prevents skin cancer in mice, as well as immunosuppression induced by UVB radiation (Nutr. Cancer 26, 183–191, 1996). This study investigated the chemopreventive potential of dl-α-tocopherol in humans through monitoring surrogate endpoint biomarkers in sun-damaged skin.
Methods
Contralateral arms of healthy human volunteers with actinic keratoses (AKs) were randomly assigned to receive either 12.5% dl-α-tocopherol or placebo in a crème base for 6 months. Changes in number of AKs, levels of p53 protein expression, proliferating cell nuclear antigen (PCNA) and polyamines were assessed along with skin and systemic vitamin E levels.
Results
Following treatment, plasma concentration levels of dl-α-tocopherol were unchanged, but skin levels were highly elevated (p<0.001). Levels of p53 and PCNA did not change significantly while number of AKs declined insignificantly in both placebo and treatment arms. Regression models demonstrated significant decreases in putrescine, spermidine, spermine, and total polyamine concentrations following treatment.
Discussion
Topically applied dl-α-tocopherol was substantially absorbed in skin, but the 6-month application did not significantly reduce numbers of pre-existing AKs on moderately to severely sun-damaged forearms. Increases in polyamine synthesis are expected during tumor initiation and promotion; conversely, the significant reductions in polyamine levels resulting from the topical dl-α-tocopherol application are consistent with reductions in tumorigenesis potential. Topical tocopherol did not normalize established sun-induced lesions, but dl-α-tocopherol induced reductions in polyamine metabolism are consistent with the inhibition of skin squamous cell carcinogenesis as seen in previous human trials and animal models.
Keywords: Actinic Keratosis, dl-α-tocopherol, p53, PCNA, p53 expression, polyamines
Introduction
Incidence of both melanoma and nonmelanoma skin cancers are increasing in the United States at an alarming rate, reflecting trends both in increasing levels of solar ultraviolet radiation reaching the Earth's surface and aging of the U.S. population (1,2). Additionally, recent data suggest skin cancer prevalence is increasing among younger adults (3, 4). The likelihood of continuance of these trends increases the urgency for the development of primary and secondary skin cancer prevention methods.
Vitamin E, a primary epidermal antioxidant rapidly depleted by oxidizing ultraviolet radiation (UVR), is a compound of interest in skin cancer prevention (5, 6). Research indicates that topical application of free, non-fatty acid conjugated vitamin E (free dl-α-tocopherol) prevents skin cancer in mice, as well as immunosuppression induced by ultraviolet-B (UVB) radiation (7, 8). These findings suggest that free dl-α-tocopherol may be a promising chemopreventive agent among humans as well. However, clinical trials using the development of skin cancer as an endpoint is logistically difficult and costly. To evaluate the potential activity of topically administered dl-α-tocopherol in participants at high risk for developing nonmelanoma skin cancers, we pursued a two-pronged strategy of monitoring dorsal forearm actinic keratoses (AKs) as well as levels of potentially relevant surrogate endpoint biomarkers (tumor suppressor protein p53, proliferating cell nuclear antigen [PCNA], and polyamine concentrations). AKs are considered precursors or intermediate endpoints of squamous cell carcinomas (SCC) development (9, 10), and are thus an obvious candidate for study. Levels of expression of p53 and PCNA are biomarkers that have been implicated in non-melanoma skin cancer carcinogenic pathways (11–15). The tumor-promotion phase of UVR exposure is characterized by production of oxygenated free radicals and increased levels of polyamines. Polyamines play an important role in cell growth and proliferation with intracellular concentrations generally high during states of rapid cell turnover as in AKs (16, 17). Studying such biomarker endpoints can not only reduce the duration and size of clinical trials, they can also provide information about possible mechanisms of action for chemopreventive agents.
The primary hypothesis for this study was that topical administration of 12.5% dl-α-tocopherol in a crème base to sun-exposed skin in humans would result in significant reductions in polyamine levels, p53 protein expression and PCNA labeling indices in AK lesions, and perhaps induce clinical reversal of those lesions and/or prevention of new ones. The secondary hypothesis was that reduction in or disappearance of AK lesions would be correlated with changes in the assessed biomarkers (p53 and/or PCNA levels and/or putrescine, spermidine, and spermine polyamine levels).
Materials and Methods
Recruitment and Visits
Fifty healthy volunteers thirty years of age or older who had at least ten discrete and clinically diagnosable AKs on each dorsal forearm were recruited to this phase II b, randomized, double-blind, placebo-controlled cancer prevention study. Exclusion criteria included current cancer or lateral forearm treatment for cancer or AKs within the past 30 days, or initial clinical chemistry levels (SMA20) outside of normal limits.
Recruited participants completed extensive baseline questionnaires including demographic characterization, dietary, medical, residential, and sun exposure histories. A one-month placebo run-in period ensured that the forearm skin was not damaged by recent sun exposure or dryness prior to the initial biopsies and also provided an estimate of compliance to the twice-daily topical application regimen. The placebo was a non-active crème base, Vanicreme® (Pharmaceutical Specialties, Inc., Rochester, MN).
Clinical staff described and demonstrated application of the study cream and the use of the provided calendar to record times of the twice-daily applications. Two tubes of cream were provided to the individual, bearing neon green or orange labels identifying the arm (right or left) to which the cream should be applied. The participant was asked to squeeze out one inch of cream onto the appropriate forearm and apply the cream to the dorsal forearm (knuckles to the crease of the elbow) until the white color was no longer visible. Participants were also asked to record any adverse effects and call the clinic staff or doctor for any severe reactions or adverse effects lasting more than twenty-four hours. Participants were asked to use a provided sunscreen (SolBar®®, Person and Covey, Glendale, CA.) as necessary. The SolBar®® sunscreen was selected for its high sun protection factor (SPF) of 50 and absence of tocopherol or other compounds known to interact with tocopherols.
After the one-month placebo run-in, participants returned to the clinic for toxicity and adherence assessments, forearm dermatological examination including outlining AKs for baseline lateral forearm photographs, and shave biopsies. Participants with estimated topical application compliance of less than 75% during the placebo run-in period were excluded.
The dermatologist selected three AK on each forearm and removed the six biopsies (three per arm), each approximately 4 mm in diameter using the shave technique. Following the biopsy procedure, participants were provided two new tubes of study cream along with new adherence calendar pages.
Forearms of each participant were randomized such that one arm received free dl-α-tocopherol (Henkel Fine Chemicals, La Grange, IL.) cream at a concentration of 12.5 grams per 100 grams of Vanicreme® (12.5%) and the other arm received placebo (Vanicreme® base with no additions). A progressive randomization program was used to ensure that the allocation of right arm versus left arm dl-α-tocopherol cream did not vary by gender, age, or initial AK count. This design guarded against the possibility that systematic differences in sun exposures for different arms could confound study results.
For the next six months, participants returned to the clinic monthly for scheduled visits at which clinical staff inquired about possible complications. If adverse events had occurred, staff inquired about severity, date of onset, duration, and date of resolution. A predetermined protocol reduced or discontinued cream application if any side effects were rated as severe. At each visit study staff also weighed the returned tubes of cream and provided a new set of study cream for the ensuing month.
At the end of six months, participants returned to the clinic for physician-administered brief physical exams, forearm dermatological exams including circling of AKs, photographs, and final biopsies. In addition to AK biopsies, three normal-looking sites per forearm were removed for assessment of dermal dl-α-tocopherol levels. Blood was drawn for a final clinical chemistry assessment with an additional 10 cc sample in a heparinized container for systemic dl-α-tocopherol analysis.
Biochemical and immunohistological assessments
In order to determine levels of free dl-α-tocopherol in plasma and skin, 250 μl ethanol (containing 0.1% BHT anti-oxidant) were added to a 250 μl-aliquot of plasma to precipitate proteins. After vortexing, the sample was extracted with hexane, dried under nitrogen, and redissolved in the high performance liquid chromatography (HPLC) mobile phase. For the skin biopsies, α-tocopherol was extracted as previously described, with minor modification (18). Briefly, skin was incubated with 0.5% collagenase and 0.2% protease (Sigma Chemical, St. Louis, MO) at 37°C for one hour. After skin homogenization, an equal volume of 1% sodium dodecyl sulfate in ethanol was added and kept at the same temperature for 30 minutes. The sample was also extracted with hexane, dried under nitrogen, and redissolved in the mobile phase. The α-tocopherol was separated using a 5-μM ultrasphere ODS column (octadecylsilica 25 cm × 4.6 mm; Beckman Instruments, Inc., San Ramon, CA) and detected at a wavelength of 290 nm. The solvent system was acetonitrile-methanol-acetic acid (60:40:0.2 v/v/v) delivered at a flow rate of 2.4 ml/min (8,19).
Skin polyamine concentrations were measured using a previously described reverse-phase HPLC assay (20) with modification (21). The HPLC effluent was monitored with a Kratos model Spectroflow 980 fluorescence detector (ABI analytical, Ramsey NJ). The excitation wavelength was set at 340 nm, and a 550 nm cut-off filter was used on the emission side. The limit of detection of dansylated polyamines in this system were less than 1 pmol. Levels of putrescine, spermidine, and spermine are reported in nmol/gm wet skin.
To assess levels of PCNA and p53, skin biopsy specimens were paraffin-embedded and cut into 3-μm sections. After deparaffinization, PCNA and p53 protein expression were measured by immunohistochemistry as previously described (11,20,21). For PCNA, immunostaining proceeded at room temperature using an avidin-biotin-based Vectastain avidin-biotin complex kit (Vector Laboratories, Burlingame, CA). The complex was visualized using 0.25 mg 3,3-diaminobenzidine/ml in PBS with 0.06% H2O2 (Sigma) added just prior to use. Light staining with hematoxylin-eosin stain (H&E) was followed by dehydration and coverslipping. For p53, immunostaining relied on a standardized streptavidin-biotin peroxidase system with a 3,3'-diaminobenzadine tetrahydrochloride chromagen and a hematoxylin counterstain (Ventana Medical Systems, Tucson, AZ) on an automated VMS 320 immunostainer (Ventana Medical Systems). PCNA and p53 labeling indices were calculated by dividing the number of labeled cells by the number of total cells (labeled and unlabeled) in the counting area and multiplying by 100.
Analytic Methods
Descriptive statistics included means, medians, standard deviations and standard errors. Initial assessment of differences in outcomes between placebo and dl-α-tocopherol arms relied on the Wilcoxon sign-rank test, since outcomes were not normally distributed. Additionally, a conditional change model that adjusts for the change on the untreated arm was used as previously described to assess the effects of α-tocopherol on number for all outcomes (19). Analyses were performed using Stata, version 10 (24). Selected secondary analyses were completed using SAS 9.1 (25) or SPSS 15.0 (26)
Results
Demographics
Table 1 summarizes gender, weight, age, and previous cancer history. As a consequence of requiring at least 10 assessable AKs for study entry, most participants were male, and the average age for both genders was just under 70. Nearly half the males had a prior history of skin cancer compared to only one of the six female participants.
Table 1.
Demographic characteristics of participants completing the six-month topical vitamin E study.
N | Weight (SE) [pounds] | Age (SE) [years] | Skin Cancer History [number] (%)1 | |
---|---|---|---|---|
Males | 36 | 182.4 (4.44) | 68.0 (1.40) | 16 (44.4) |
Females | 6 | 139.7 (8.27) | 67.3 (1.40) | 1 (16.7) |
All | 42 | 176.3 (4.60) | 68.0 (1.22) | 17 (40.5) |
Participants who answered “uncertain” to a history of skin cancer were considered as having a negative history.
Participant Attrition
Five of the original fifty participants did not complete the six-month topical application regimen. Of these, two participants discontinued the study prior to being randomized, one after experiencing an aversion to the venipuncture procedure, and the other due to a diagnosis of lymphocytic leukemia. Post-randomization, two participants discontinued the study due to ill health unrelated to the topical application regimen (recurrent problems following gall bladder surgery and death from cardiovascular disease). The third individual, who discontinued study medication post-randomization, was unable to achieve the required seventy-five percent compliance to the topical application regimen, although compliance had been achieved during the run-in period.
Of the forty-five participants completing the application regimen, three were nevertheless excluded from analysis of number of AKs. Of these, one participant had continued an oral treatment regimen (25,000 IU vitamin A daily) shown to be effective in reducing squamous cell skin cancer development in a previous chemoprevention trial (22,23). For the other two, examination of the remaining contents of returned study cream tubes indicated that mislabeled tubes had been distributed during the study, so that each forearm had received both placebo and dl-α-tocopherol creams rather than a single cream throughout the study period. Thus, data from forty-two individuals were used in the analysis of number of AKs. The excluded participants, seven men and one woman, did not vary in age or initial characteristics from the 42 individuals who were fully evaluable.
The left arm biopsy on one individual was lost, so data from only forty-one individuals could be used in the analysis of p53 and PCNA. Due to the limited availability of biopsy material, complete polyamine profiles were assessed for both arms of only 37 of the 41 study participants. For all analyses, we considered the use of an intent-to-treat approach. However, due to the study design, all subjects received both placebo and treatment (albeit on opposite arms), so that loss of a subject affected treatment and control groups identically. Thus, all analyses were conducted only on individuals for whom all data were available.
Left versus Right Arm
Baseline values of clinical outcome measures (AKs, p53, PCNA) did not differ by left versus right arm, or treatment versus control group (results not shown here). Moreover, in no analysis of those outcomes did arm status ever achieve statistical significance. Therefore, for simplicity, arm status was not included in subsequent tables or discussion.
Skin and plasma levels of dl-α-tocopherol
Levels of dl-α-tocopherol are presented in Table 2. Concentration of free dl-α-tocopherol was much higher in treated than in placebo arms, indicating that absorption into the skin occurred. However, as expected, there was no change in plasma levels of free dl-α-tocopherol from baseline to end of study.
Table 2.
Plasma and Skin Levels of free dl-α-tocopherol (n = 42)
α-Tocopherol | ||||
---|---|---|---|---|
|
SE | p-value of difference | ||
Skin | ||||
Treated Arms | 545.5 | 73.2 | ||
Placebo Arms | 17.2 | 1.5 | (p<.001) | |
Plasma | ||||
Baseline Levels | 12.5 | 0.8 | ||
End of Study | 12.5 | 0.7 | (p=.978) |
Number of AKs
Table 3 presents the number of AKs at the time of randomization and after six months of treatment with placebo or dl-α-tocopherol. There were 8 individuals at baseline and 6 individuals at the end of treatment where AKs on one or both arms were so dense and confluent that the dermatologist had to classify them as `too numerous to count'. For the purpose of analysis, including descriptive statistics, these cases have been treated as equal to 78 AKs, the highest countable number recorded in the data. These cases were distributed nearly identically across treatment status, due to the randomization design. Sensitivity analyses were conducted (results not shown) excluding these individuals and the pattern of results reported in table 3 did not change in terms of sign or significance. Thus, the findings are robust to the transformation of `too numerous to count' status to a count of 78.
Table 3.
Number of actinic keratoses by treatment group (n = 42)
Baseline1 | End of Study1 | Change2 | |||||||
---|---|---|---|---|---|---|---|---|---|
|
SE |
|
SE |
|
SE | ||||
Placebo | 34.3 | 3.8 | 26.3 | 3.8 | −8.0 | 2.2 | |||
Treated | 34.0 | 3.8 | 28.0 | 3.7 | −6.0 | 2.2 |
Only the initial number of AKs on the placebo arm was normally distributed
Change variables are normally distributed
The third column in table 3 indicates the difference in number of AKs from baseline to end of treatment. The number of AKs declined significantly on arms treated with dl-α-tocopherol (p=.004). However, they also declined significantly, and to a greater extent, on arms treated with placebo (p=.0002). The greater decrease in AKs among placebo arms was not statistically significant at p=0.29. These changes amount to an approximately 20–25% decline in the number of AKs overall.
Skin p53 and PCNA expression and polyamine levels
The expression of p53 and PCNA over time is shown in table 4 along with polyamine levels. No statistically significant differences for p53 and PCNA existed between placebo and treatment arms at baseline. Expression of p53 and PCNA increased in the placebo arms from baseline to end of study. However, neither increase in the placebo arm proved statistically significant (for p53, p=0.18; for PCNA, p=0.85). p53 expression declined in treated arms and PCNA expression increased, but these changes also were not statistically significant (for p53, p=.98; for PCNA, p=.10). Changes in biomarker expression did not differ significantly across placebo versus treatment arms (for p53, p=0.12; for PCNA, p=0.48). The overall levels of putrescine, spermidine, spermine and total polyamine concentrations significantly decreased following treatment with free dl-α-tocopherol (p<0.0001, p<0.0001, p=0.002, and p<0.0001, respectively) compared to placebo. No significant difference in the ratio of spermidine to spermine was evident between the treatment arms indicating similar decrements in the individual polyamines in response to the topical treatment.
Table 4.
Levels of p53 protein, PCNA expression (n = 41), and polyamine concentrations (n=37) in forearm biopsy samples from topical vitamin E study participants. Information is included for only those participants for whom complete analytic specimen sets were available.
Baseline | End of Studv | Change | |||||
---|---|---|---|---|---|---|---|
mean% expression | S.E. | mean% expression | S.E. | mean% expression | S.E. | p value* | |
p53 | |||||||
Placebo | 20.3 | 2.4 | 25.4 | 2.9 | 5.1 | 3.1 | 0.1215 |
Treated | 21.1 | 2.9 | 20.1 | 2.1 | −1.0 | 3.3 | |
PCNA | |||||||
Placebo | 8.4 | 1.0 | 9.0 | 1.1 | 0.6 | 1.5 | 0.4800 |
Treated | 6.6 | 1.0 | 8.6 | 1.2 | 2.0 | 1.5 |
mean | mean | mean %change | |||||
---|---|---|---|---|---|---|---|
Polyamines | nmol/g | S.E. | nmol/g | S.E. | nmol/g | S.E. | p value* |
Putrescine | |||||||
Placebo | 120.83 | 7.73 | 131.59 | 10.14 | 10.76 | 12.2 | 0.0004 |
Treated | 139.12 | 10.68 | 89.50 | 5.50 | −49.62 | 9.3 | |
Spermidine | |||||||
Placebo | 292.17 | 14.80 | 309.94 | 17.77 | 17.77 | 14.8 | 0.0074 |
Treated | 302.10 | 15.17 | 259.6 | 11.40 | −42.72 | 13.2 | |
Spermine | |||||||
Placebo | 205.51 | 9.78 | 213.59 | 12.22 | 8.08 | 13.1 | 0.0955 |
Treated | 246.77 | 10.26 | 226.61 | 8.69 | −20.16 | 8.9 | |
Total polyamines | |||||||
Placebo | 618.51 | 28.55 | 655.12 | 34.57 | 36.61 | 33.5 | 0.0014 |
Treated | 687.98 | 29.13 | 575.49 | 21.05 | −112.49 | 24.8 | |
Spermidine:spermine ratio | |||||||
Placebo | 1.43 | 0.03 | 1.47 | 0.04 | 0.04 | 0.05 | 0.1048 |
Treated | 1.26 | 0.06 | 1.15 | 0.04 | −0.11 | 0.05 |
Wilcoxon signed rank test on change variables
Effects of free dl-α-tocopherol on number of AKs
Table 5 shows results of conditional change models for each of the three main outcomes. The first row captures the effects of free dl-α-tocopherol on number of AKs after controlling for baseline number of AKs. The findings are consistent with those presented in Table 3, confirming that free dl-α-tocopherol was not associated with any change in number of AKs beyond that associated with placebo.
Table 5.
Regression models including coefficients, for effect of topical application of free dl-α-tocopherol on number of actinic keratoses and expression of p53, PCNA or polyamine levels.
Overall effect of free dl-α-tocopherol 95% C.I. p-value | Effect of baseline level 95% C.I. p-value | R2 | |||||
---|---|---|---|---|---|---|---|
AK 1 | 2.0 | (−1.3, 5.3) | 0.226 | 0.3 | (−0.6, −0.1) | 0.007 | 0.17 |
p53 2 | −6.1 | (−12.9, 0.7) | 0.078 | −1.0 | (−1.3, −0.6) | >0.001 | 0.44 |
PCNA 2 | 1.3 | (−1.3, 4.0) | 0.308 | −0.5 | (−0.8, −0.3) | 0.001 | 0.27 |
Putrescine 3 | −60.4 | (−79.6,−41.2) | <0.0001 | −1.04 | (−1.3, −0.8) | <0.0001 | 0.65 |
Spermidine 3 | −60.5 | (−86.2,−34.8) | <0.0001 | −1.29 | (−1.6, −1.0) | <0.0001 | 0.70 |
Spermine 3 | −28.2 | (−45.2,−11.3) | 0.002 | −1.25 | (−1.5, −1.0) | <0.0001 | 0.80 |
Total Polyamines 3 | 149.1 | (−214.3,−83.9) | <0.0001 | −2.18 | (−3.6, −2.0) | <0.0001 | 0.69 |
Spermidine/spermine ratio 3 | 0.005 | (−.10, 0.11) | 0.11 | 1.04 | (0.7, 1.3) | <0.0001 | 0.60 |
N=42
N=41
N=37
Effects of free dl-α-tocopherol on levels of p53 and PCNA
The next two rows in table 5 show similar results for the two biomarker outcomes. In each case, 95% confidence intervals for the intercept term indicate no statistically significant effect of free dl-α-tocopherol at the α=.05 level. Note that for p53, there was a marginally significant effect (p<0.10).
Safety Monitoring and Toxicity
Each monthly visit included the completion of a Safety Monitoring and Toxicity Report to ensure that all potential signs or adverse symptoms to the treatment were assessed. Initially and at each subsequent visit, participants were asked whether they had experienced any of the following: redness, itchiness, burning, dryness, or any other unexpected sensation on each arm. For each potential reaction, the severity was categorized as mild, moderate, or severe. The same form was completed if a participant called between clinic visits to report problems or when participants who had previously reported problems were called for follow-up. The study protocol required follow-up on any moderate or severe symptom. Nineteen of the 42 participants reported an absence of all signs or symptoms throughout the entire period of follow-up. Only 5% of the Safety Monitoring and Toxicity reports indicated any moderate or severe symptom. Table 6 provides the distribution of the most commonly reported signs and symptoms by treatment status. Redness and itchiness were the most frequently reported symptoms, but were reported with equal frequency among arms receiving free dl-α-tocopherol or placebo treatment. These data do not suggest that the free dl-α-tocopherol treatment had a systematic effect on toxicity. Presumably, reactions also occurred in response to the delivery vehicle, the Vanicreme® base.
Table 6.
Distribution of moderate and severe symptoms by treatment status.
Symptom | Total Number of Reports | Arm(s) Affected | ||
---|---|---|---|---|
Treated | Placebo | Both Arms | ||
Redness | 5 | 2 | 2 | 1 |
Itchiness | 5 | 2 | 2 | 1 |
Burning1 | 3 | 1 | 0 | 0 |
Dryness | 1 | 1 | 0 | 0 |
Information on which arm(s) experienced burning was not properly recorded in two cases.
Discussion
The current study shows that topically applied dl-α-tocopherol reduced polyamine content in the skin of patients with large numbers of established AKs on the forearms. Elevated polyamine levels are characteristically seen in many types of neoplastic cells and tissues. O'Brien and colleagues have demonstrated that in transgenic mice overexpression of ornithine decarboxylase in skin leads to changes in tissue polyamine levels, particularly putrescine, and can modulate the development and maintenance of the neoplastic phenotype (29, 30). Joshi further hypothesized that polyamine synthesis is expected to promote endothelial cell proliferation and therefore angiogenesis (31). This reinforces the known role of polyamine biosynthesis in mediating skin tumor initiation and promotion (29 – 33).
The main findings of the present study can be summarized by the following statements. Daily topical application resulted in substantial uptake of free dl-α-tocopherol into the forearm skin. The significantly increased concentrations of tocopherol in skin was not associated with reductions in the number of established AK lesions (normalization of skin) or in the expression of skin biomarkers expected to mediate such changes, p53 and PCNA. Skin putrescine, spermidine, spermine, and the total polyamine concentrations were appreciably reduced relative to initial and placebo concentration levels. This finding is similar to observations of Khettab et al. who demonstrated that topical vitamin E inhibited the production of free radicals by approximately 60% and caused a significant reduction in polyamine biosynthesis (p < 0.001) in the epidermis of UV irradiated hairless mice (34). In the present study, vitamin E significantly reduced skin polyamine concentrations, modifications consistent with the inhibition of squamous cell skin carcinogenesis as seen in previous human trials and animal models.
Although the number of AKs declined significantly over the course of this study, they did not appear to do so in response to treatment with free dl-α-tocopherol. Declines occurred in both the placebo control and the experimental intervention groups, suggesting that perhaps the SolBar® 50 sunscreen daily applications were responsible for the change. Thompson et al reported significant regression effects of sunscreens administered daily over a period of a year to a group of Australians randomized to sunscreen application or placebo cream (35). Alternatively, the decline in AKs may have been due to an emollient effect masking the scale and roughness associated with AK rather than a physiological change that would be likely to affect the development of subsequent skin cancer. The lack of a true free dl-α-tocopherol effect on AKs is also reinforced by the lack of a statistically significant effect of the intervention on p53 or PCNA skin biopsy labeling indices.
In the conditional change model for the overall effect of free dl-α-tocopherol, the 95% confidence interval (−1.3, 5.3) suggested that the study was powered to detect an effect of ± 3.3 AKs as statistically significant. Referring back to Table 3, this would represent a 10% change in AK count from the baseline levels of approximately 34 AKs per arm. Thus, the study was sufficiently powered to detect a clinically significant change in numbers of AKs due to treatment. In a similarly designed previous study of topical DFMO application, polyamine level decrements resulted in a 23% reduction in AK count (36). Two primary differences distinguish the topical DFMO from the current free dl-α-tocopherol study: (1) mean initial AK count of 28 among DFMO study subjects indicating a less sun damaged population in comparison to the current study, and (2) no sunscreen was provided during the DFMO study. Although the previous DFMO study also randomly assigned the arm (right or left) receiving the topical intervention cream, DFMO effectiveness was substantially greater in the right arm. Differential UVR likely due to left arm exposure during automobile driving was believed to affected study results. However, we currently cannot rule out the possibility that the addition of the highly protective (SPF 50) sunscreen to prevent differential sun exposure altered study results through an emollient effect or by adding UVR protection that altered the intervention time required for polyamine changes to significantly affect AK count. This topical study was not designed to accurately map size and location of specific AK lesions and capture potential subtle changes in AK appearance. The study's negative findings therefore suggest that six months of daily applications of topical free dl-α-tocopherol has little or no normalizing effect on moderately to severely sun damaged skin.
The vast majority of adult sunscreen preparations contain α-tocopherol acetate or another esterified fatty acid as an emollient. Previously, our group reported that α-tocopherol acetate (or succinate) could potentiate UVB-skin carcinogenesis in a mouse model (8). Furthermore, in a companion human study, we showed that the long term application of α-tocopherol acetate to sun damaged skin resulted in a build-up of high concentrations of the esterified vitamin E compound in epidermal skin, a potentially adverse effect for skin cancer prevention (19).
In contrast, Gensler et al had demonstrated that free dl-α-tocopherol applied topically to a UVB-induced, mouse skin carcinogenesis model proved significantly protective (7). Although the results of our present study indicated free dl-α-tocopherol applied topically for 6 months to participant's arms containing multiple AKs did not significantly reduce the number of AK lesions, there was no evidence of a promotional effect on AK proliferation. Nevertheless, the continued incorporation of esterified forms of dl-α-tocopherol in commercially available sunscreens as an “inactive ingredient” emollient may pose a public health problem.
Topical application of free dl-α-tocopherol was well tolerated and resulted in substantial increases in skin vitamin E levels. The regimen was not associated with reduction in the number of established AK lesions nor biomarkers expected to mediate skin normalization. An inherent disadvantage to ensuring a clinical assessable endpoint such as the reduction in the number of AK lesions, is the selection of moderately to severely sun damaged skin indicative of substantial prior tumor promotion. While unsuccessful at reducing the numbers of AK lesions, the application of free dl-α-tocopherol significantly reduced skin polyamine concentrations, modulations characteristically associated with the inhibition of neoplastic phenotypes and AK development.
Footnotes
Supported in part by grants CA-27502 and CA-23074 from the National Institutes of Health, Bethesda, MD 20892
REFERENCES
- 1.Johnson TM, Dolan OM, Hamilton TA, Lu MC, Swanson NA, Lowe L. Clinical and histologic trends of melanoma. J. Am. Acad. Dermatol. 1998;38:681–686. doi: 10.1016/s0190-9622(98)70196-3. [DOI] [PubMed] [Google Scholar]
- 2.Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol. 1997;133:1263–1270. [PubMed] [Google Scholar]
- 3.Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294:681–690. doi: 10.1001/jama.294.6.681. [DOI] [PubMed] [Google Scholar]
- 4.Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among U.S. Caucasian young adults. J. Invest. Dermatol. 2008;128:2905–2908. doi: 10.1038/jid.2008.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Rhie G, Shin MH, Seo JY, Choi WW, Cho KH, Kim KH, Park KC, Eun HC, Chung JH. Aging- and photoaging-dependent changes of enzymic and nonenzymic antioxidants in the epidermis and dermis of human skin in vivo. J Invest Dermatol. 2001;117:1212–1217. doi: 10.1046/j.0022-202x.2001.01469.x. [DOI] [PubMed] [Google Scholar]
- 6.Thiele JJ. Oxidative targets in the stratum corneum. A new basis for antioxidative strategies. Skin Pharmacol. Appl. Skin Physiol. 2001;14(Suppl 1):87–91. doi: 10.1159/000056395. [DOI] [PubMed] [Google Scholar]
- 7.Gensler HL, Magdaleno M. Topical vitamin E inhibition of immunosuppression and tumorigenesis induced by ultraviolet irradiation. Nutr. Cancer. 1991;15:97–106. doi: 10.1080/01635589109514117. [DOI] [PubMed] [Google Scholar]
- 8.Gensler HL, Aickin M, Peng Y-M, Xu M. Importance of the form of topical vitamin E for prevention of photocarcinogenesis. Nutr. Cancer. 1996;26:183–191. doi: 10.1080/01635589609514474. [DOI] [PubMed] [Google Scholar]
- 9.Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795–797. doi: 10.1016/s0140-6736(88)91658-3. [DOI] [PubMed] [Google Scholar]
- 10.Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 2000;42:S4–S7. doi: 10.1067/mjd.2000.103342. [DOI] [PubMed] [Google Scholar]
- 11.Nelson MA, Einspahr JG, Alberts DS, Balfour CA, Wymer JA, Welch KL, Salasche SJ, Bangert JL, Grogan TM, Bozzo PO. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 1994;85:23–29. doi: 10.1016/0304-3835(94)90234-8. [DOI] [PubMed] [Google Scholar]
- 12.Einspahr JG, Alberts DS, Warneke JA, Bozzo Pl, Basye J, Grogan TM, Nelson MA, Bowden GT. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia. 1999;1:468–475. doi: 10.1038/sj.neo.7900061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Pennys NS, Bogaert M, Serfling U, Sisto M. PCNA expression in cutaneous keratinous neoplasms and verruca vulgaris. Am. J. Pathol. 1992;141:139–142. [PMC free article] [PubMed] [Google Scholar]
- 14.Saida T, Dohi S, Sadaki M, Tokuda Y, Idegawa S, Takasaki Y. Distribution patterns and frequency of proliferating cells in cutaneous keratinocytic neoplasms. J. Am. Acad. Dermatol. 1992;26:744–748. doi: 10.1016/0190-9622(92)70104-n. [DOI] [PubMed] [Google Scholar]
- 15.Geary WA, Cooper PH. Proliferating cell nuclear antigen (PCNA) in common epidermal lesions. J. Cutaneous Pathol. 1992;19:458–468. doi: 10.1111/j.1600-0560.1992.tb01598.x. [DOI] [PubMed] [Google Scholar]
- 16.Russell DH. The roles of the polyamines, putrescine, spermidine, and spermine in normal and malignant tissues. Life Sci. 1973;13:1635–1647. doi: 10.1016/0024-3205(73)90111-2. [DOI] [PubMed] [Google Scholar]
- 17.Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin. Cancer Res. 2002;8:149–155. [PubMed] [Google Scholar]
- 18.Peng YM, Peng YS, Lin Y. A nonsaponification method for the determination of carotenoids, retinoids, and tocopherols in solid human tissues. Cancer Epidemiol. Biomark. Prev. 1993;2:139–144. [PubMed] [Google Scholar]
- 19.Alberts DS, Goldman R, Xu MJ, Dorr RT, Quinn J, Welch K, Guillen-Rodriguez J, Aickin M, Peng YM, Loescher L, Gensler H. Disposition and metabolism of topically administered alpha-tocopherol acetate: A common ingredient of commercially available sunscreens and cosmetics. Nutr. Cancer. 1996;26:193–201. doi: 10.1080/01635589609514475. [DOI] [PubMed] [Google Scholar]
- 20.Minocha SC, Minocha R, Robie CA. High-performance liquid chromatographic method for the determination of dansyl-polyamines. J Chromatogr. 1990;511:177–183. [Google Scholar]
- 21.Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, Nelson MA. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis. 1997;18:1195–1202. doi: 10.1093/carcin/18.6.1195. [DOI] [PubMed] [Google Scholar]
- 22.Einspahr J, Alberts DS, Aickin M, Welch K, Bozzo P, Levine N, Grogan T. Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. Cancer Epidemiol. Biomarker Prev. 1996;5:343–348. [PubMed] [Google Scholar]
- 23.Einspahr J, Alberts DS, Aickin M, Welch K, Bozzo P, Grogan T, Nelson M. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin. Cancer Epidemiol. Biomarkers Prev. 1997;6:583–587. [PubMed] [Google Scholar]
- 24.Stata Corporation . Stata statistical software: release 10.0. College Station (TX): [Google Scholar]
- 25.SAS Institute, Incorporated . SAS Statistical Software System version 9.1. SAS Campus Drive Cary; N.C 27513: 1989–1996. Copyright. [Google Scholar]
- 26.SPSS for Windows . Release 9.0. SPSS Inc.; Chicago: 1999. [Google Scholar]
- 27.Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q, Peng YM, Alberts DS, Southwest Skin Cancer Prevention Study Group Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomark Prev. 1997;6(11):949–956. [PubMed] [Google Scholar]
- 28.Moon TE, Levine N, Cartmel B, Bangert JL. Retinoids in the prevention of skin cancer. Cancer Letters. 1997;114:203–205. doi: 10.1016/s0304-3835(97)04663-6. [DOI] [PubMed] [Google Scholar]
- 29.O'Brien TG, Megosh LC, Gilliard G, Peralta Soler A. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res. 1997;57:2630–2637. [PubMed] [Google Scholar]
- 30.Peralta Soler A, Gilliard G, Megosh L, George K, O'Brien TG. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res. 1998;58:1654–1659. [PubMed] [Google Scholar]
- 31.Joshi M. The importance of L-arginine metabolism in melanoma: an hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. Free Rad. Biol. Med. 1997;22:573–578. doi: 10.1016/s0891-5849(96)00339-5. [DOI] [PubMed] [Google Scholar]
- 32.Seiler N, Knödgen B. Effects of ultraviolet light on epidermal polyamine metabolism. Biochem. Med. 1979;21:168–181. doi: 10.1016/0006-2944(79)90069-3. [DOI] [PubMed] [Google Scholar]
- 33.Cohen SS, editor. A Guide to the Polyamines. Oxford University Press; New York: 1998. [Google Scholar]
- 34.Kettab N, Amory M-C, Briand G, Bousquet B, Combre A, Forlot P, Barey M. Photoprotective effect of vitamins A and E on polyamine and oxygenated free radical metabolism in hairless mouse epidermis. Biochim. 1998;70:1709–1713. doi: 10.1016/0300-9084(88)90028-4. [DOI] [PubMed] [Google Scholar]
- 35.Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N. Engl. J. Med. 1993;329:1147–1151. doi: 10.1056/NEJM199310143291602. [DOI] [PubMed] [Google Scholar]
- 36.Alberts DS, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, Peng YM, Goldman R, Foote JA, Warneke JA, Salasche S, Roe DJ, Bowden GT. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomark Prev. 2000;9:1281–1286. [PubMed] [Google Scholar]